Breaking News Instant updates and real-time market news.

2022-10-28 09:24:45 AAPL Apple $144.98 / -4.52 (-3.02%) 09:24 10/28/22 10/28 09:24 10/28/22 09:24	Apple guidance 'better than feared,' says Morgan Stanley Morgan Stanley analyst Erik Woodring said Apple's September quarter beat and "in-line to above Street" December quarter guidance was "better than feared" and "illustrates the consistency of Apple's ecosystem." The report last night doesn't settle the consumer debate, but "Apple remains best of breed," said Woodring, who keeps an Overweight rating and $177 price target on Apple shares.

2022-10-28 09:24:45

AAPL

Apple

$144.98 / -4.52 (-3.02%)

09:24

10/28/22

10/28

09:24

10/28/22

09:24

Apple guidance 'better than feared,' says Morgan Stanley

Morgan Stanley analyst Erik Woodring said Apple's September quarter beat and "in-line to above Street" December quarter guidance was "better than feared" and "illustrates the consistency of Apple's ecosystem." The report last night doesn't settle the consumer debate, but "Apple remains best of breed," said Woodring, who keeps an Overweight rating and $177 price target on Apple shares.

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	BioCardia sees cash runway into 3Q23 » 08:19 03/29/23 03/29 08:19 03/29/23 08:19 BCDA BioCardia $2.19 / +0.1 (+4.78%) Net cash used in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BCDA BioCardia $2.19 / +0.1 (+4.78%) 03/06/23 BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial 02/01/23 BioCardia and CellProthera extend partnership agreement 12/22/22 BioCardia CEO says coming year offers potential for catalysts 12/15/22 BioCardia announces $3.6M private placement of common stock BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/17/22 Alliance Global Partners BioCardia price target lowered to $6 from $11.50 at Alliance Global Partners 11/11/22 Dawson James BioCardia downgraded to Neutral from Buy at Dawson James BCDA BioCardia $2.19 / +0.1 (+4.78%) 08:19 Today BioCardia reports 2022 EPS (67c) vs. (75c) last year 11/09/22 BioCardia reports Q3 EPS (17c), consensus (23c) BCDA BioCardia $2.19 / +0.1 (+4.78%) 12/08/22 Biotech Alert: Searches spiking for these stocks today 16:30 Today BioCardia - BCDA
Earnings	BioCardia reports 2022 EPS (67c) vs. (75c) last year » 08:19 03/29/23 03/29 08:19 03/29/23 08:19 BCDA BioCardia $2.19 / +0.1 (+4.78%) Reports 2022 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BCDA BioCardia $2.19 / +0.1 (+4.78%) 03/06/23 BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial 02/01/23 BioCardia and CellProthera extend partnership agreement 12/22/22 BioCardia CEO says coming year offers potential for catalysts 12/15/22 BioCardia announces $3.6M private placement of common stock BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/17/22 Alliance Global Partners BioCardia price target lowered to $6 from $11.50 at Alliance Global Partners 11/11/22 Dawson James BioCardia downgraded to Neutral from Buy at Dawson James BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/09/22 BioCardia reports Q3 EPS (17c), consensus (23c) BCDA BioCardia $2.19 / +0.1 (+4.78%) 12/08/22 Biotech Alert: Searches spiking for these stocks today 16:30 Today BioCardia - BCDA
Hot Stocks	Olink technology enables further development of South African research » 08:18 03/29/23 03/29 08:18 03/29/23 08:18 OLK Olink $19.83 / -1.8 (-8.32%) Olink announced that the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly OLK Olink $19.83 / -1.8 (-8.32%) 03/21/23 Olink announces Bruno Rossi joins the company as Chief Commercial Officer 03/06/23 Olink implementation of technology at NUS Medicine 02/28/23 Olink establishes agreement with RGC to scale proteomics efforts 11/03/22 Olink announces 1,000 peer-reviewed articles citing use of PEA technology OLK Olink $19.83 / -1.8 (-8.32%) 01/05/23 Scotiabank Olink initiated with an Outperform at Scotiabank 01/04/23 Scotiabank Olink initiated with an Outperform at Scotiabank 12/14/22 Canaccord Olink initiated with a Buy at Canaccord OLK Olink $19.83 / -1.8 (-8.32%) 02/21/23 Olink sees FY23 revenue $192M-$200M, consensus $193.48M 02/21/23 Olink reports Q4 EPS 5c, consensus 1c 01/09/23 Olink sees FY23 revenue $192M-$200M, consensus $199.3M 01/09/23 Olink narrows FY22 revenue view to $139.4M-$139.8M from $138M-142M 19 Jan OLK Olink $19.83 / -1.8 (-8.32%) 02/21/23 Fly Intel: Pre-market Movers 01/18/23 Fly Intel: After-Hours Movers
Hot Stocks	Verses, SimWell partner to enhance digital twin stimulations with KOSMOS » 08:17 03/29/23 03/29 08:17 03/29/23 08:17 VRSSF Verses Technologies / + VERSES Technologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News VRSSF Verses Technologies / + 03/22/23 Verses Technologies closes second tranche of convertible debenture financing 03/01/23 Verses closes $5M tranche, announces upsize of convertible debenture financing 02/27/23 Verses Technologies announces convertible debenture financing up to C$5M 02/23/23 Verses Technologies announces General Intelligent Agent, codenamed GIA
Hot Stocks	Crispr Therapeutics announces departure of board member » 08:16 03/29/23 03/29 08:16 03/29/23 08:16 CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) CRISPR Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/27/23 Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact 03/13/23 Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed 12/27/22 Cathie Wood's ARK Investment bought 10.8K shares of Crispr Therapeutics today 12/19/22 Crispr Therapeutics appoints Harding as SVP, Head of Business Development CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/21/23 Bernstein Crispr Therapeutics initiated with a Market Perform at Bernstein 03/18/23 Citi Crispr Therapeutics price target lowered to $55 from $63 at Citi 03/17/23 Bryan Garnier Crispr Therapeutics initiated with a Buy at Bryan Garnier 03/06/23 Baird Baird starts Crispr at Neutral with strong launch priced in CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/22/23 Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y 04/03/23 The Future of Oncology Virtual Symposium CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/21/23 Crispr Therapeutics options imply 4.4% move in share price post-earnings 02/14/23 Crispr Therapeutics options imply 4.9% move in share price post-earnings 01/05/23 Crispr Therapeutics call volume above normal and directionally bullish
Hot Stocks	G Medical Innovations enters into agreement with AdventHealth Central Florida » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) G Medical Innovations… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) 03/27/23 G Medical Innovations, MiCare Path announce joint collaboration 02/13/23 G Medical Innovations receives patent from USPTO for vital sign sensors 01/30/23 G Medical Innovations granted patent by USPTO for vital signs sensors 12/05/22 G Medical Innovations receives two U.S. patents for monitoring products
Hot Stocks	Caribou initiates dose expansion portion of CB-010 ANTLER Phase 1 trial » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 08:12 Today Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Hot Stocks	First Solar announces facility in India awarded financial incentives » 08:13 03/29/23 03/29 08:13 03/29/23 08:13 FSLR First Solar $210.01 / +0.08 (+0.04%) First Solar announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options FSLR First Solar $210.01 / +0.08 (+0.04%) 03/01/23 Origis Energy enters agreeent with First Solar for 2 GW of modules 02/28/23 First Solar announces Lightsource bp places multi-year order for 4 GW 01/12/23 First Solar completes sale of 141 MW Luz del Norte power plant to Toesca 12/19/22 First Solar to replace Fortune Brands in S&P 500 at open on 12/19 FSLR First Solar $210.01 / +0.08 (+0.04%) 03/23/23 Barclays First Solar price target raised to $230 from $162 at Barclays 03/15/23 Credit Suisse First Solar price target raised to $163 from $152 at Credit Suisse 03/14/23 Argus First Solar price target raised to $261 from $176 at Argus 03/09/23 Citi First Solar transferred with Neutral rating at Citi FSLR First Solar $210.01 / +0.08 (+0.04%) 02/28/23 First Solar sees FY23 EPS $7.00-$8.00, consensus $4.77 02/28/23 First Solar reports Q4 EPS (7c), consensus (15c) 02/28/23 Notable companies reporting after market close 10/27/22 First Solar reports Q3 EPS (46c), consensus (27c) FSLR First Solar $210.01 / +0.08 (+0.04%) 12/02/22 Chinese solar producers dodged U.S. tariffs, WSJ reports FSLR First Solar $210.01 / +0.08 (+0.04%) 03/06/23 What You Missed This Week in EVs and Clean Energy 03/03/23 What You Missed On Wall Street On Friday 03/03/23 What You Missed On Wall Street This Morning 02/28/23 Fly Intel: After-Hours Movers FSLR First Solar $210.01 / +0.08 (+0.04%) 03/08/23 Unusually active option classes on open March 8th 03/06/23 Early notable gainers among liquid option names on March 6th 03/03/23 Early notable gainers among liquid option names on March 3rd 03/01/23 Early notable gainers among liquid option names on March 1st
Hot Stocks	Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 11/21/22 Caribou Biosciences announces FDA clearance of IND application for CB-011 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Recommendations	Viking Therapeutics price target raised to $25 from $15 at Maxim » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 Viking Therapeutics initiates Phase 1 study of novel formulation of VK2735 03/28/23 Viking Therapeutics jumps 32% to $12.06 after Phase 1 VK2735 trial results 03/28/23 Viking Therapeutics announces results from Phase 1 trial of VK2735 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 06:15 Today Raymond James Viking Therapeutics price target raised to $35 from $12 at Raymond James 03/28/23 BTIG Viking Therapeutics price target raised to $31 from $20 at BTIG 03/28/23 Oppenheimer Viking Therapeutics price target raised to $30 from $20 at Oppenheimer 03/28/23 Stifel Stifel reiterates Buy on Viking Therapeutics, raises price target to $25 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 02/08/23 Viking Therapeutics reports Q4 EPS (26c), consensus (23c) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/21/23 Viking Therapeutics call volume above normal and directionally bullish 03/16/23 Viking Therapeutics call volume above normal and directionally bullish 03/08/23 Viking Therapeutics call volume above normal and directionally bullish 02/17/23 Viking Therapeutics call volume above normal and directionally bullish

Hot Stocks	Enphase Energy launches new IQ8 microinverters in France, the Netherlands » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 ENPH Enphase Energy $193.50 / -2.28 (-1.16%) Enphase Energy announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/20/23 Enphase Energy expands IQ8 microinverter deployments in Virginia 03/13/23 Enphase Energy expands IQ8 microinveter deployments in Utah 03/06/23 Enphase Energy expands IQ8 microinverter deployments in Illinois 02/26/23 Fly Intel: Top five weekend stock stories ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/22/23 Susquehanna Enphase upgraded to Positive on recent pullback at Susquehanna 03/22/23 Susquehanna Enphase Energy upgraded to Positive from Neutral at Susquehanna 03/20/23 Raymond James Enphase Energy upgraded to Outperform from Market Perform at Raymond James 03/09/23 Citi Enphase Energy transferred with Buy rating at Citi ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/07/23 Enphase Energy sees Q1 revenue $700M-$740M, consensus $690.46M 02/07/23 Enphase Energy reports Q4 EPS $1.51, consensus $1.24 02/07/23 Notable companies reporting after market close 10/25/22 Enphase Energy sees Q4 revenue $680M-$720M, consensus $660.21M ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/25/23 Corning, Enphase among key U.S. Clean Energy players, Barron's says ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/20/23 What You Missed On Wall Street On Monday 03/20/23 What You Missed On Wall Street This Morning ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/23/23 Early notable gainers among liquid option names on March 23rd 03/20/23 Early notable gainers among liquid option names on March 20th 03/06/23 Early notable gainers among liquid option names on March 6th 02/27/23 Early notable gainers among liquid option names on February 27th
Hot Stocks	Akari announces Poland, U.K. approve new manufacturing process for nomacopan » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AKTX Akari Therapeutics / + Akari Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research AKTX Akari Therapeutics / + 02/21/23 Akari Therapeutics presents case study from Phase 3 Part A trial of nomacopan 02/15/23 Akari announces pre-clinical development progress toward IND for GA treatment 02/13/23 Akari Therapeutics announces acceleration of Phase 3 trial of nomacopan 11/10/22 Akari Therapeutics announces FDA granted RPDD to nomacopan AKTX Akari Therapeutics / + 12/05/22 H.C. Wainwright Akari Therapeutics initiated with a Buy at H.C. Wainwright 11/01/22 Alliance Global Partners Akari Therapeutics initiated with a Buy at Alliance Global Partners
Upgrade	Anhui Conch Cement upgraded to Neutral from Sell at Goldman Sachs » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) 11/15/22 HSBC Anhui Conch Cement upgraded to Buy from Hold at HSBC 08/28/22 Goldman Sachs Anhui Conch Cement downgraded to Sell from Neutral at Goldman Sachs
Hot Stocks	Kala Pharmaceuticals appoints Francis Mah as chief medical advisor » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) Kala Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/27/23 Kala announces safety update from Cohort 1 of CHASE Phase 2b trial 02/14/23 Kala recruiting for study of KPI-012 in participants with PCED 01/19/23 Kala Pharmaceuticals falls 10% to $15.90 after equity offering 12/30/22 Kala Pharmaceuticals trading resumes KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/06/23 H.C. Wainwright Kala Pharmaceuticals price target raised to $20 from $12 at H.C. Wainwright 12/29/22 Wedbush IND acceptance sets up Kala for execution year in 2023, says Wedbush 11/09/22 Wedbush Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush 05/24/22 H.C. Wainwright Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/03/23 Kala Pharmaceuticals reports Q4 EPS ($7.97) vs ($33.94) last year 11/08/22 Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 01/19/23 Fly Intel: After-Hours Movers 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/29/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 Fly Intel: After-Hours Movers 04/24/23 Kala Pharmaceuticals, Inc.
Hot Stocks	NV5 awarded $11M essential infrastructure projects in California, New Mexico » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 NVEE NV5 Global $100.90 / +0.02 (+0.02%) NV5 Global announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NVEE NV5 Global $100.90 / +0.02 (+0.02%) 03/13/23 NV5 Global announces $11M in engineering, planning awards 03/06/23 NV5 Global announces Axim Geospatial awarded $9M in national security contracts 03/02/23 NV5 Global acquires Gaudet Associates 02/23/23 NV5 Global announces acquisition of Axim Geospatial NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/24/23 Baird NV5 Global price target lowered to $130 from $150 at Baird 08/05/22 Lake Street NV5 Global price target raised to $175 from $136 at Lake Street NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/23/23 NV5 Global reports Q4 EPS $1.21 , consensus $1.57 11/03/22 NV5 Global reports Q3 adjusted EPS $1.50, consensus $1.45
Hot Stocks	DoubleDown announces results of 2023 Annual General Meeting » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 DDI DoubleDown $8.09 / +0.08 (+1.00%) DoubleDown Interactive… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research DDI DoubleDown $8.09 / +0.08 (+1.00%) 01/11/23 DoubleDown to acquire i-Gaming company SuprNation for $35M 12/28/22 DoubleDown announces results of EGM held on December 28 DDI DoubleDown $8.09 / +0.08 (+1.00%) 09/15/22 Macquarie DoubleDown initiated with an Outperform at Macquarie 07/11/22 B. Riley Investors have overlooked DoubleDown, says B. Riley 06/28/22 B. Riley DoubleDown price target lowered to $20 from $30 at B. Riley
Initiation	Engie Brasil initiated with an Outperform at Scotiabank » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) Scotiabank analyst Renato… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) 03/07/23 UBS Engie Brasil upgraded to Buy from Neutral at UBS 01/10/23 JPMorgan Engie Brasil upgraded to Overweight from Neutral at JPMorgan 10/14/22 JPMorgan Engie Brasil upgraded to Neutral from Underweight at JPMorgan 08/08/22 JPMorgan Engie Brasil downgraded to Underweight from Neutral at JPMorgan
Recommendations	LuxUrban Hotels price target raised to $7 from $6 at Maxim » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 02/16/23 LuxUrban Hotels announces preferred U.S.hotel partnership with NusaTrip 02/08/23 LuxUrban in MLA deals for LA hotel O and 101 Bogart Street in NY, no terms 12/02/22 LuxUrban Hotels names Jimmie Chatmon COO 12/01/22 LuxUrban Hotels acquires Townhouse Hotel in South Beach, FL LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 12/12/22 Maxim LuxUrban Hotels initiated with a Buy at Maxim LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 01/18/23 LuxUrban Hotels affirms FY22 net rental revenue and EBITDA guidance
Hot Stocks	Rapt Therapeutics announces initiation of Phase 2a trial of RPT193 » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) RAPT Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/10/23 Rapt Therapeutics says $2M of cash held at Silicon Valley Bank 12/08/22 Rapt Therapeutics reports Phase 1/2 results of FLX475 in advanced cancer 11/17/22 Rapt Therapeutics falls 7% to $19.70 after $75M common stock offering RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/15/23 Capital One Rapt outlook 'remains steady' despite shift in timeline, says Capital One 03/15/23 Cantor Fitzgerald Rapt Therapeutics price target lowered to $40 from $44 at Cantor Fitzgerald 03/15/23 H.C. Wainwright Rapt Therapeutics price target lowered to $43 from $50 at H.C. Wainwright 01/04/23 Guggenheim Rapt Therapeutics initiated with a Buy at Guggenheim RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/14/23 Rapt Therapeutics reports Q4 EPS (64c), consensus (66c) 11/10/22 Rapt Therapeutics reports Q3 EPS (63c), consensus (67c) 18 Nov RAPT Rapt Therapeutics $17.86 / +0.02 (+0.11%) 03/16/23 Biotech Alert: Searches spiking for these stocks today 11/17/22 Fly Intel: After-Hours Movers
Hot Stocks	Harmony Biosciences reports accelerated timeline for Phase 3 hypersomnia study » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) Harmony Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Harmony Biosciences 'disagrees' with Scorpion Capital's 'assertions' 01/09/23 Novavax names John Jacobs as new CEO, succeeding Stanley Erck 01/06/23 Harmony Biosciences CEO John Jacobs stepping down 11/15/22 Harmony Biosciences director sells $9.12M in common stock HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Mizuho Harmony short report 'misleading,' 'perhaps even sensational,' says Mizuho 03/28/23 Raymond James Raymond James says buy Harmony on weakness after 'low quality' short report 02/22/23 Mizuho Harmony Biosciences price target lowered to $60 from $70 at Mizuho 01/04/23 Piper Sandler Harmony Biosciences price target raised to $70 from $62 at Piper Sandler HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 02/21/23 Harmony Biosciences reports Q4 non-GAAP EPS $1.01, consensus 58c 11/01/22 Harmony Biosciences reports Q3 non-GAAP EPS 95c vs 41c last year HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Scorpion: Filing Citizen's Petition to request withdrawal of Harmony drug 03/28/23 Scorpion Capital issues investigative report on Harmony Biosciences HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 03/28/23 Harmony plunges as Scorpion seeks FDA withdrawal of Wakix approval 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations

Hot Stocks	Pacira announces FDA clearance of sNDA for EXPAREL label » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 PCRX Pacira $39.93 / -0.15 (-0.37%) Pacira BioSciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PCRX Pacira $39.93 / -0.15 (-0.37%) 03/27/23 Court upholds decision to dismiss Pacira lawsuit against ASA 03/22/23 Pacira announces Yvonne Greenstreet to retire from Board 02/28/23 Pacira sees 2023 EXPAREL net sales $570M-$580M 02/23/23 Pacira, LPGA partner to raise awareness of non-opioid pain management solutions PCRX Pacira $39.93 / -0.15 (-0.37%) 03/03/23 Barclays Pacira price target lowered to $80 from $90 at Barclays 03/01/23 H.C. Wainwright Pacira price target raised to $71 from $69 at H.C. Wainwright 02/10/23 H.C. Wainwright Pacira price target lowered to $69 from $76 at H.C. Wainwright 01/31/23 Wedbush Pacira assumed with an Outperform at Wedbush PCRX Pacira $39.93 / -0.15 (-0.37%) 02/28/23 Pacira reports Q4 adjusted EPS 80c, consensus 83c 01/05/23 Pacira sees FY22 EPS 'at least' $2.50, consensus $2.77 11/03/22 Pacira reports Q3 adjusted EPS 64c, consensus 76c 10/13/22 Pacira reports preliminary Q3 revenue $167.5M, consensus $172.72M
Hot Stocks	Baltimore Orioles select Shift4 to process payments for ballpark concessions » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) "We're thrilled… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Shift4 Payments rises 9.1% 01/17/23 Shift4 Payments partners with Real Salt Lake 11/22/22 Shift4 Payments falls -8.5% 11/07/22 Shift4 Payments rises 10.6% FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 03/16/23 Truist Shift4 Payments price target raised to $87 from $80 at Truist 03/01/23 RBC Capital Shift4 Payments price target raised to $80 from $70 at RBC Capital 03/01/23 Piper Sandler Shift4 Payments price target raised to $85 from $69 at Piper Sandler 03/01/23 DA Davidson Shift4 Payments price target raised to $80 from $65 at DA Davidson FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Shift4 Payments sees FY23 revenue $2.5B-$2.7B. consensus $2.74B 02/28/23 Shift4 Payments reports Q4 adjusted EPS 47c, consensus 38c 02/27/23 Notable companies reporting before tomorrow's open 02/27/23 Notable companies reporting before tomorrow's open FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 02/28/23 Fly Intel: Pre-market Movers 12/30/22 Buy/Sell: Wall Street's top 5 stock calls this week 12/29/22 What You Missed On Wall Street On Thursday 12/29/22 What You Missed On Wall Street This Morning FOUR Shift4 Payments $68.98 / +1.9 (+2.83%) 03/28/23 Shift4 Payments call volume above normal and directionally bullish 03/03/23 Shift4 Payments put volume heavy and directionally bearish 03/01/23 Shift4 Payments call volume above normal and directionally bullish
Hot Stocks	Precigen: First patient dosed in Phase 1/1b study of of PRGN-3007 » 08:07 03/29/23 03/29 08:07 03/29/23 08:07 PGEN Precigen / + Precigen announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options PGEN Precigen / + 01/24/23 Precigen reports results from Phase 1 PRGN-2012 study 01/11/23 Precigen CEO says will focus on clinical programs' path to licensure in 2023 12/12/22 Precigen announces 'positive' Phase 1 dose escalation data from PRGN-3006 study PGEN Precigen / + 01/30/23 Cantor Fitzgerald Precigen price target raised to $10 from $7 at Cantor Fitzgerald 12/28/22 Cantor Fitzgerald Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks 11/18/22 Cantor Fitzgerald Precigen initiated with an Overweight at Cantor Fitzgerald 11/18/22 Cantor Fitzgerald Precigen initiated with an Overweight at Cantor Fitzgerald PGEN Precigen / + 03/06/23 Precigen reports Q4 EPS (11c), consensus (10c) 11/09/22 Precigen reports Q3 EPS (4c), consensus 2c 25 Jan PGEN Precigen / + 01/27/23 Biotech Alert: Searches spiking for these stocks today 01/25/23 What You Missed On Wall Street On Wednesday 01/25/23 What You Missed On Wall Street This Morning 01/25/23 Fly Intel: Pre-market Movers PGEN Precigen / + 03/06/23 Precigen options imply 35.3% move in share price post-earnings 02/08/23 Largest borrow rate increases among liquid names
Hot Stocks	Third Harmonic Bio expects cash to fund requirements through next 12 months » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) Cash and cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 Third Harmonic Bio discontinues Phase 1b study of THB001 THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/16/22 Jefferies Third Harmonic Bio downgraded to Hold from Buy at Jefferies 12/16/22 LifeSci Capital Third Harmonic Bio downgraded to Market Perform at LifeSci Capital 12/15/22 Morgan Stanley Morgan Stanley downgrades Third Harmonic after 'disappointing' discontinuation 12/15/22 Morgan Stanley Third Harmonic Bio downgraded to Equal Weight from Overweight at Morgan Stanley THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 08:06 Today Third Harmonic Bio reports 2022 EPS ($2.62), consensus ($2.39) 15 Sep THRD Third Harmonic Bio $4.30 / +0.02 (+0.47%) 12/15/22 What You Missed On Wall Street On Thursday 12/15/22 What You Missed On Wall Street This Morning
Recommendations	Biolase price target lowered to $1 from $5 at Maxim » 08:06 03/29/23 03/29 08:06 03/29/23 08:06 BIOL Biolase / + Maxim analyst Anthony… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings BIOL Biolase / + 01/04/23 Sonendo unit files patent infringement lawsuit against Biolase BIOL Biolase / + 01/20/23 Lake Street Biolase assumed with a Buy at Lake Street 11/11/22 Maxim Biolase price target lowered to $5 from $10 at Maxim 05/20/22 Lake Street Biolase initiated with a Buy at Lake Street BIOL Biolase / + 03/28/23 Biolase sees Q1 revenue over $10.0M, consensus $12.23M 03/28/23 Biolase reports Q4 EPS ($1.28), consensus (64c) 01/18/23 Biolase targets revenue growth by at least 25% in 2023, consensus $55.06M 01/18/23 Biolase sees 2022 revenue $48.4M-$48.8M, consensus $47.58M

Events

Earnings calls, analyst events, roadshows and more

BTMD
Today at 08:30

Biote - BTMD Conference Calls
GLYC
Today at 08:30

GlycoMimetics - GLYC Conference Calls
MINM
Today at 08:30

Minim - MINM Conference Calls
BLUE
Today at 08:30

Bluebird Bio - BLUE Conference Calls
UNF
Today at 09:00

UniFirst - UNF Conference Calls
RDW
Today at 09:00

Redwire - RDW Conference Calls
BOSC
Today at 09:00

BOS Better Online Solutions - BOSC Conference Calls
IBEX
Today at 09:00

Ibex - IBEX Conference Calls
CLH
Today at 09:00

Clean Harbors Firm Sponsored Meetings

Virtual Meeting
PAYX
Today at 09:30

Paychex - PAYX Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	YGF X YGF YanGuFang IPO Managers: EF Hutton Priced at: $4.00 2M Shares ZJYL X ZJYL Jin Medical IPO Managers: Prime Number Priced at: $8.00 1M Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	SYT X SYT Syla Technologies IPO Managers: Boustead $8.00 1.875M Shares
Fri	No deals

View All Syndicate Announcements »

Apple guidance 'better than feared,' says Morgan Stanley

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access